Dublin, June 27, 2017 -- Research and Markets has announced the addition of the "Biochips (Microarrays/Microfluidics) Global Market - Forecast to 2023" report to their offering.
The global biochips market is expected to grow at double digit CAGR to reach $17,851.1 million by 2023
Biochips market is mainly classified into technologies, products, application and end-users. The global biochips market is broadly classified as micro arrays and microfluidics based on technology.
Revolution in the field of genomics, proteomics as well as rapid drug discovery increased the demand for biochips. In addition, increase in diagnosis and treatment of cancer and genetic diseases, approval for personalized medicines and invention of novel technologies in biochips drives the market of biochips. Standardization and quality assurance of biochips, technological ease in handling the biochips especially in the areas of diagnosis and treatment, high cost along with ethical and social issues hinders the market growth.
Lifestyle changes owing to increase in cancer, diabetes and hypertension patients, early diagnosis and treatment of diseases, advancement of biochips with its wide application areas shows that biochip market has vast opportunities in the coming years.
North America accounts for the highest market share in 2016 and followed by Europe. Steep rise in genetic diagnosis, huge corporate outsourcing for drug discovery, increase in personalized medicines and favourable government policies makes U.S. the leader of Biochips market. However, Asian countries especially China and Japan are the fastest growing regions with its growing demand for biochips and increasing research investments.
Factors Influencing Market
Drivers and Opportunities
- Increase in Usage of Biochips in Cancer Diagnostics
- Biochips Preference in Personalized Medicine
- Widening Application Market
- Emerging Asia Pacific Market
- Increased Government Funding
Restraints and Threats
- High Cost of Biochips
- Lack of Standardization
- Limited Skilled Personnel to Work on Biochips
- Stringent Regulations
- Adoption of Ngs
Key Topics Covered:
1 Executive Summary
2 Introduction
3 Market Analysis
4 Biochips Global Market, by Technology
5 Biochips Global Market, by Products
6 Biochips Global Market, by Applications
7 Biochips Global Market, by End-Users
8 Regional Market Analysis
9 Competitive Landscape
10 Major Companies
- Abbott Laboratories
- Agilent Technologies, Inc.
- Becton Dickinson and Company
- Bio-Rad Laboratories
- Danaher Corporation
- Fluidigm Corporation
- GE Healthcare
- Illumina, Inc.
- Perkinelmer, Inc.
- Thermofisher Scientific Inc.
For more information about this report visit https://www.researchandmarkets.com/research/hwq6d3/biochips
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Biotechnology


MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
First Western Ship Transits Strait of Hormuz Since Iran War Began
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Apple Turns 50: From Garage Startup to AI Crossroads
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Britain Courts Anthropic Amid US Defense Department Dispute
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 



